NCT07303907Phase 2Recruiting

A Phase 2A Trial of DT402 for Autism Spectrum Disorder

Study sponsor: Definium Therapeutics US, Inc.

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2027-08Estimated

Enrollment · participants20Estimated

Source updated2026-09-02Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Study details

Conditions studied

Autism Spectrum Disorder; ASD

Treatments or interventions studied

DT402 (R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA))DrugAlso known as MM402, R-MDMA, MDMA

Primary outcomes · main study measures

Read the study measures

measure: Change from Baseline in 11-point Numerical Rating Scale (NRS) scores; description: The NRS is an 11-point PRO scale used to measure the severity or intensity of effects from 0 (no effect) to 10 (high severity or intensity of effect). It consists of various items related to both positive and negative effects in the autism patient population.; timeFrame: Baseline, pre-dose and 2, 4, 6, 8, and 24 hours post-dose and day 15

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history